Superworth

TuHURA Biosciences price to book ratio HURA

Market value divided by the book value of the company's net assets, since 2014.

Today, Oct 23, 2026
7.5×
10-year median
0.1×
Against its 10-year history
89th
percentile: 0 is its lowest day, 100 its highest
10-year range
0.0× to 190×
Peer median
1.6×

TuHURA Biosciences' price to book ratio is 7.5× as of Oct 23, 2026.

That is above its ten-year median of 0.1×, higher than on 89% of days in the last ten years.

Over that time it ranged from 0.0× in Nov 2022 to 190× in Feb 2025.

The median for 10 large drugmakers of a similar size is 1.6×.

Price to book ratio over time

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far7.5×1.6×8.9×
20252.4×2.4×190×
2024127×81.9×177×
20230.9×0.0×1.0×
20220.0×0.0×0.1×
20210.0×0.0×0.1×
20200.0×0.0×4.2×
20190.0×0.0×0.2×
20180.1×0.0×0.1×
20170.1×0.0×0.7×
20160.2×0.2×13.1×
20153.1×0.3×3.1×
20141.5×0.7×1.7×

Against its peers

Companies in Drug Manufacturers - General nearest TuHURA Biosciences' size, closest first, today.

CompanyPrice to book ratio
HURATuHURA Biosciences7.5×
NATRNatures Sunshine Products1.3×
LFVNLifevantage2.2×
SPROSpero Therapeutics1.5×
ATNMActinium Pharmaceuticals1.6×
ARVNArvinas0.8×
PBYIPuma Biotechnology4.1×
IRWDIronwood Pharmaceuticalsn/m
ZVRAZevra Therapeutics2.7×
CRMDCorMedix1.3×
COLLCollegium Pharmaceutical2.4×
Peer median1.6×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on TuHURA Biosciences

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.